Showing 20,141 - 20,160 results of 109,021 for search '(( 5 ((a decrease) OR (mean decrease)) ) OR ( a ((point decrease) OR (nn decrease)) ))', query time: 1.23s Refine Results
  1. 20141

    TMD-5 intrinsic Trp fluorescence assay. by Xiaohui Wang (19899)

    Published 2012
    “…(b), Pentamidine decreases Trp emission fluorescence intensity of TMD-5 in 150 µM C14 betaine and 50 mM HEPES (pH = 7.4) buffer in a dose-dependent manner. …”
  2. 20142

    Inhibition correlates with cellular PmV levels. by Luca Gambini (826027)

    Published 2015
    “…DC6 clone expresses PmV-GFP chimera under regulation of the native promoter [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142509#pone.0142509.ref015" target="_blank">15</a>]; G6 clone, the PmV-GFP-DD chimera under regulation of the native promoter (this paper) and #3 clone (episomally expressing PmV-GFP chimera under <i>Hsp86-5'</i>, a strong and constitutive promoter) [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0142509#pone.0142509.ref015" target="_blank">15</a>]. …”
  3. 20143

    MCPyV circALTO can be translated. by Rong Yang (107028)

    Published 2021
    “…<p>(A) CircALTOs do not inhibit MCPyV miRNA function in vitro. 293 cells were transfected with <i>Renilla</i> luciferase reporter with a 300 nucleotide region complementary to the MCPyV miRNA and the indicated plasmids including a MCPyV-miRNA-M1 expression plasmid (derived from isolate MCV350), pCDNA3.1 control vector, pCDNA circALTO1 (pcircALTO1) or pCDNA circALTO2 (pcircALTO2) expression plasmid. …”
  4. 20144
  5. 20145

    V2G controls parameters [36]. by Mahmoud M. Hussein (16965014)

    Published 2023
    “…Both of these components are designed for autonomous vehicle-to-grid (V2G) devices. The proposed control technique is applied to a three-area power system, where the V2G scheme is located in Area-1. …”
  6. 20146

    Dynacortin facilitates polarization of chemotaxing cells-5 by Cathryn Kabacoff (40205)

    Published 2011
    “…A total of 2.5 M actin was present in each sample. …”
  7. 20147

    Plants components in five-flower remedy [24]. by Walaiporn Plirat (17775628)

    Published 2025
    “…This study aimed to explore the potential antimalarial and neuroprotective properties of the five-flower remedy (FFR), a traditional herbal formulation, in experimental cerebral malaria (ECM). …”
  8. 20148

    Five multi-target tracking evaluation indexes. by Wenshun Sheng (21485393)

    Published 2025
    “…<div><p>A real-time stable multi-target tracking method based on the enhanced You Only Look Once-v8 (YOLOv8) and the optimized Simple Online and Realtime Tracking with a Deep association metric (DeepSORT) for real-time stable multi-target tracking (S-YOFEO) is proposed to address the issue of target ID transformation and loss caused by the increase of practical background complexity. …”
  9. 20149
  10. 20150

    Ctcf and Smarca5 interact in AML cells. by Martina Dluhosova (519144)

    Published 2014
    “…D Smarca5 at ICR upon Ctcf knockdown. Occupancy of Smarca5 (lysates from 1A) by ChIP. …”
  11. 20151

    Five onset times and results for musculoskeletal simulation. by Jiyoun Kim (3364571)

    Published 2022
    “…<p>(A) The five different onset times were at 12%, 18%, 24%, 30%, and 36% of the gait cycle. …”
  12. 20152

    Image_5_Genetic Variation in CCL5 Signaling Genes and Triple Negative Breast Cancer: Susceptibility and Prognosis Implications.JPEG by Jingxuan Shan (4711089)

    Published 2019
    “…We found a highly significant association between the CCND1 rs614367-TT genotype (OR = 5.14; P = 0.004) and TNBC risk, and identified a significant association between the rs614367-T allele and decreased PFS in TNBC. …”
  13. 20153

    Table_5_Genetic Variation in CCL5 Signaling Genes and Triple Negative Breast Cancer: Susceptibility and Prognosis Implications.DOCX by Jingxuan Shan (4711089)

    Published 2019
    “…We found a highly significant association between the CCND1 rs614367-TT genotype (OR = 5.14; P = 0.004) and TNBC risk, and identified a significant association between the rs614367-T allele and decreased PFS in TNBC. …”
  14. 20154

    Patients’ responses to EQ5-D items. by Walid Al-Qerem (3760027)

    Published 2024
    “…</p><p>Result</p><p>This study included 68.8% females, with a median age of 58 (50–64) years. The median EQ5-D index score was 0.66 (0.41–0.78). …”
  15. 20155

    Annotation of Allosteric Compounds to Enhance Bioactivity Modeling for Class A GPCRs by Lindsey Burggraaff (6243110)

    Published 2020
    “…Endogenous ligands, such as hormones and neurotransmitters, bind to the orthosteric site, while synthetic ligands may bind to orthosteric or allosteric sites, which has become a focal point in drug discovery. Usually, such allosteric modulators bind to a protein noncompetitively with its endogenous ligand or substrate. …”
  16. 20156

    Annotation of Allosteric Compounds to Enhance Bioactivity Modeling for Class A GPCRs by Lindsey Burggraaff (6243110)

    Published 2020
    “…Endogenous ligands, such as hormones and neurotransmitters, bind to the orthosteric site, while synthetic ligands may bind to orthosteric or allosteric sites, which has become a focal point in drug discovery. Usually, such allosteric modulators bind to a protein noncompetitively with its endogenous ligand or substrate. …”
  17. 20157

    Annotation of Allosteric Compounds to Enhance Bioactivity Modeling for Class A GPCRs by Lindsey Burggraaff (6243110)

    Published 2020
    “…Endogenous ligands, such as hormones and neurotransmitters, bind to the orthosteric site, while synthetic ligands may bind to orthosteric or allosteric sites, which has become a focal point in drug discovery. Usually, such allosteric modulators bind to a protein noncompetitively with its endogenous ligand or substrate. …”
  18. 20158

    Annotation of Allosteric Compounds to Enhance Bioactivity Modeling for Class A GPCRs by Lindsey Burggraaff (6243110)

    Published 2020
    “…Endogenous ligands, such as hormones and neurotransmitters, bind to the orthosteric site, while synthetic ligands may bind to orthosteric or allosteric sites, which has become a focal point in drug discovery. Usually, such allosteric modulators bind to a protein noncompetitively with its endogenous ligand or substrate. …”
  19. 20159
  20. 20160